Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Line item | CIS Pharma | Gea | Ivermedi | Welfare International | Mermisi |
|---|---|---|---|---|---|
| Total Revenue | 65,941 | 46,251 | 45,937 | 40,243 | — |
| Total COGS | -24,855 | -29,418 | -35,869 | -24,198 | — |
| Gross Profit | 41,086 | 16,833 | 10,068 | 16,045 | — |
| Gross Margin | 62.3% | 36.4% | 21.9% | 39.9% | — |
| Total Operating Expenses | -7,024 | -13,152 | -11,163 | -3,308 | — |
| EBITDA | 34,062 | 3,681 | -1,095 | 12,737 | — |
| EBITDA Margin | 51.7% | 8.0% | -2.4% | 31.6% | — |
| Total D&A | -290 | -295 | 0 | -11 | — |
| EBIT / Operating Income | 33,772 | 3,386 | -1,095 | 12,725 | — |
| Total Other Income | -229 | 6,026 | 703 | -4,589 | — |
| Profit Before Tax | 33,543 | 9,281 | -350 | 8,008 | — |
| Total Income Tax | -293 | -416 | -643 | -44 | — |
| Net Profit / (Loss) | 33,250 | 8,866 | -993 | 7,964 | — |
| Net Margin | 50.4% | 19.2% | -2.2% | 19.8% | — |
| Total Interest Expense | — | -131 | — | -128 | — |
| Total Interest Income | — | — | 42 | — | — |
Not every picked company reports every selected year — FY2024: no filing for Mermisi. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| CIS Pharma | Pharma | 51.7% | 97th pct | 110 |
| Welfare International | Pharma | 31.6% | 75th pct | 110 |
| Gea | Pharma | 8.0% | 35th pct | 110 |
| Ivermedi | Pharma | -2.4% | 11th pct | 110 |
| Mermisi | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.